- Home
- FNWD vs AGEN Comparison
FNWD vs AGEN Comparison
Compare FNWD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWD
- AGEN
- Stock Information
- Founded
- FNWD 1994
- AGEN 1994
- Country
- FNWD United States
- AGEN United States
- Employees
- FNWD N/A
- AGEN N/A
- Industry
- FNWD Savings Institutions
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNWD Finance
- AGEN Health Care
- Exchange
- FNWD Nasdaq
- AGEN Nasdaq
- Market Cap
- FNWD 137.3M
- AGEN 142.8M
- IPO Year
- FNWD N/A
- AGEN 2000
- Fundamental
- Price
- FNWD $31.85
- AGEN $4.28
- Analyst Decision
- FNWD Buy
- AGEN Buy
- Analyst Count
- FNWD 1
- AGEN 2
- Target Price
- FNWD $34.00
- AGEN $14.50
- AVG Volume (30 Days)
- FNWD 17.8K
- AGEN 456.4K
- Earning Date
- FNWD 10-23-2025
- AGEN 11-11-2025
- Dividend Yield
- FNWD 1.51%
- AGEN N/A
- EPS Growth
- FNWD N/A
- AGEN N/A
- EPS
- FNWD 1.24
- AGEN N/A
- Revenue
- FNWD $63,780,000.00
- AGEN $101,706,000.00
- Revenue This Year
- FNWD N/A
- AGEN $60.49
- Revenue Next Year
- FNWD $7.77
- AGEN N/A
- P/E Ratio
- FNWD $25.64
- AGEN N/A
- Revenue Growth
- FNWD N/A
- AGEN N/A
- 52 Week Low
- FNWD $26.12
- AGEN $1.38
- 52 Week High
- FNWD $33.50
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- FNWD 53.93
- AGEN 44.68
- Support Level
- FNWD $31.53
- AGEN $3.78
- Resistance Level
- FNWD $32.97
- AGEN $4.80
- Average True Range (ATR)
- FNWD 0.90
- AGEN 0.26
- MACD
- FNWD -0.18
- AGEN -0.01
- Stochastic Oscillator
- FNWD 18.48
- AGEN 40.34
About FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).